Mauna Kea Technologies SAS

Research Mauna Kea Technologies SAS (ALMKT) on Bullrun: valuation model: 338.5% undervalued, market cap EUR 30.28M, P/E 1.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALMKT
• ExchangePA
• CountryFrance
• SectorHealthcare
• IndustryMedical Devices
• CurrencyEUR
• Valuation signal338.5% undervalued
• Market capEUR 30.28M
• P/E1.6
• Financial periodFY2024
• RevenueEUR 7.66M
• Revenue growth-27.0%
• Net income-EUR 10.40M
• Free cash flow-EUR 6.54M
• Gross margin84.1%

Valuation Snapshot

Bullrun's latest valuation model marks Mauna Kea Technologies SAS as 338.5% undervalued; latest market cap is EUR 30.28M; P/E is 1.6.

About Mauna Kea Technologies SAS

Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications.

Frequently asked questions

Is Mauna Kea Technologies SAS overvalued or undervalued?

Bullrun's valuation model currently marks Mauna Kea Technologies SAS as 338.5% undervalued.

What is Mauna Kea Technologies SAS's market cap?

Mauna Kea Technologies SAS's market capitalization is EUR 30.28M.

What is Mauna Kea Technologies SAS's P/E ratio?

Mauna Kea Technologies SAS's price-to-earnings (P/E) ratio is 1.6.

What does Mauna Kea Technologies SAS do?

Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications.